Company profile: Agilis Biotherapeutics
1.1 - Company Overview
Company description
- Provider of DNA-based therapeutics for genetic disorders, focused on rare central nervous system diseases caused by single-gene defects. Its technology enables precise targeting and restoration of lost gene function while avoiding unintended off-target effects.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Agilis Biotherapeutics
EG 427
HQ: France
Website
- Description: Provider of pinpoint gene therapy using non-replicative HSV-1 vectors. Offers EG110A for neurogenic bladder dysfunction and overactive bladder; a platform delivering large genes with precise control and long-term expression for peripheral nervous system disorders; vector engineering with specific promoters for targeted sensory or autonomic neuronal subsets; and R&D expanding to chronic indications, including central nervous system neurons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EG 427 company profile →
CRISPR Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary CRISPR/Cas9 gene-editing platform and therapies to treat serious diseases, including CASGEVY™ (exagamglogene autotemcel), approved in some countries for sickle cell disease and transfusion-dependent beta thalassemia; CTX112, an investigational allogeneic CD19 CAR T therapy; and ex vivo and in vivo gene-editing and cell therapy approaches using viral and non-viral delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CRISPR Therapeutics company profile →
Kate Therapeutics
HQ: United States
Website
- Description: Provider of AAV-based gene therapies targeting genetically defined muscle and heart diseases, supported by the DELIVER capsid engineering platform for evolving tissue-targeted AAV variants, MyoAAV muscle-tropic capsids for skeletal and cardiac delivery, and cargo technologies to enhance regulation, targeting, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kate Therapeutics company profile →
Elsie Biotechnologies
HQ: United States
Website
- Description: Provider of RNA therapeutics and oligonucleotide discovery technologies, including a proprietary ultra-high throughput platform that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery, and P(V) chemistry technologies with novel reagents and processes to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elsie Biotechnologies company profile →
Kriya Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for ophthalmology, neurology, and metabolic diseases, including KRIYA-825 for geographic atrophy (inhibiting C3/C5; one-time suprachoroidal), KRIYA-586 for thyroid eye disease (blocking IGF1 receptor), KRIYA-839 for diabetes (insulin and glucokinase), KRIYA-497 for NASH (FGF21), and KRIYA-748 and KRIYA-382 for trigeminal neuralgia and focal epilepsy via chemogenetically gated ion channels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kriya Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Agilis Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Agilis Biotherapeutics
2.2 - Growth funds investing in similar companies to Agilis Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Agilis Biotherapeutics
4.2 - Public trading comparable groups for Agilis Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →